TrialPhase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
Trial details
- Registry ID
- NCT03920228
- Phase
- Phase 2, Phase 3
PVLA
Palvella Therapeutics, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
8Trials in this database
8Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceVALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
Trial details
- Registry ID
- NCT04520750
- Phase
- Phase 3
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Trial details
- Registry ID
- NCT04893486
- Phase
- Phase 2
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
Trial details
- Registry ID
- NCT05050149
- Phase
- Phase 2
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Trial details
- Registry ID
- NCT05180708
- Phase
- Phase 3
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Trial details
- Registry ID
- NCT06239480
- Phase
- Phase 3
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Trial details
- Registry ID
- NCT06653842
- Phase
- Phase 2
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Trial details
- Registry ID
- NCT07552077
- Phase
- Phase 2
Latest recorded trial changes
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
NCT06653842 · Palvella Therapeutics, Inc.
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Dec 2025
+ After
21 Nov 2025
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
NCT06239480 · Palvella Therapeutics, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
40 participants (planned)
+ After
51 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Jan 2026
+ After
14 Jan 2026
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting